re-emergent threat of equine herpesvirus-1 neurologic disease peter j. timoney department of...
TRANSCRIPT
Re-emergent Threat of Equine Herpesvirus-1 Neurologic DiseaseRe-emergent Threat of Equine Herpesvirus-1 Neurologic Disease
Peter J. TimoneyPeter J. Timoney
Department of Veterinary ScienceGluck Equine Research CenterUniversity of Kentucky, Lexington, KY 40546-0099
Department of Veterinary ScienceGluck Equine Research CenterUniversity of Kentucky, Lexington, KY 40546-0099
Respiratory
Outcomes of EHV-1 Infection in Horses
Ack. Dr. G. Allen (2008)
Abortion
Neonatal DeathNeurological
(EHM)
General features –
Equine Rhinopneumonitis
► Contagious disease of equids endemic in vast majority of domesticated equid populations.
► Term encompasses range of syndromes caused by either EHV-1 or EHV-4.
► Of 5 herpesviruses known to infect the horse, EHV-1 & EHV-4 are the 2 of greatest veterinary medical significance.
► Believed EHV-1 / EHV-4 have co-evolved with horses over millions of years.
► Neither virus of public health significance.3/14
EHV-1 and EHV-4 Infections
EHV-1 Infection not only of respiratory tract epithelium and associated lymphatic glands but also vascular endothelium especially of nasal mucosa, lung, adrenal, thyroid and in the case of some strains, CNS and endometrium.
EHV-4 Infection restricted primarily to respiratory tract epithelium and associated lymph glands. Some strains can set up a leukocyte-associated viremia.
3/14
Industry Concerns
► EHV-1 best known for its economic impact
as a cause of contagious abortion
worldwide.
► EHM of concern not only economically but
also from a welfare viewpoint because of
the distressing nature of the disease.
► Lack of a commercial vaccine of proven
capability to prevent EHM.3/14
Equine Herpesvirus Myeloencephalopathy
1966 -
First definitive association between EHV-1 and
myeloencephalopathy following isolation of the
virus from brain and spinal cord of a horse with
severe neurologic disease. (Saxegaard, F.,
Nord. Vet. Med., 1966).
3/14
Equine Herpesvirus Myeloencephalopathy
► Syndrome recorded with increasing frequency over past 5-10 years, can be associated with high morbidity & case fatality rate.
► Usually a sequel to a primary respiratory infection, febrile episode or abortion.
► Can occur in horses of any age, breed or either gender.
► Nature of illness dependent on location & severity of lesions in CNS.
► Disease most frequently associated with infection with neuropathogenic strains of EHV-1.
General features –
3/14
Equine Herpesvirus-1 Myeloencephalopathy
► Many outbreaks of EHM associated with
venues / premises where significant
numbers of horses are congregated
together.
► Conditions at shows, etc, conducive to
respiratory transmission of EHV-1 by direct
/ indirect means.
3/14
Increase in Incidence of Outbreaks of EHV-1 Neurologic Disease, 1970 - 2006
Increase in Incidence of Outbreaks of EHV-1 Neurologic Disease, 1970 - 2006
Time intervalTime interval
No. of neurologic disease outbreaks (US and UK) from which virus or
viral DNA were available
No. of neurologic disease outbreaks (US and UK) from which virus or
viral DNA were available
1970 – 751976 – 801981 – 851986 – 901991 – 95
1996 – 20002001 – 2006
1970 – 751976 – 801981 – 851986 – 901991 – 95
1996 – 20002001 – 2006
134656
33
134656
33
Ack: Dr. G.P. Allen
Equine herpesvirus myeloencephalopathy
caused by the hypervirulent, mutant
(neuropathogenic) strain of the virus
designated by USDA a potentially
emergent disease of the horse.
(USDA: APHIS: VS: CEAH: Center for
Emerging Issues Information Sheet,
January 2007)
3/14
Association of Novel Genotype of EHV-1 with Neurologic Disease
► Majority of severe and sometimes
extensive EHM events associated with
novel virus genotype.
► Novel genotype characterised by single
point mutation on catalytic subunit of viral
DNA polymerase.
► Guanine substituted for adenine at position
2254.3/14
-- GTC GAC TAC ---- GTC GAC TAC --
-- GTC AAC TAC ---- GTC AAC TAC -- (neutral)Asparagine (neutral)Asparagine
Aspartic acid (acidic)Aspartic acid (acidic)
Replicase geneReplicase gene
EHV-1 DNAEHV-1 DNA
Abortion Strains:Abortion Strains:
Paralytic Strains: Paralytic Strains:
Nucleotide Substitution in Neuropathogenic Strains of EHV-1
Nucleotide Substitution in Neuropathogenic Strains of EHV-1
Ack: Dr. G.P. Allen
Outbreaks of EHV-1 Neurologic Disease in USA, 2000 - 2006
--- Genotype of Virus Isolates ---
Outbreaks of EHV-1 Neurologic Disease in USA, 2000 - 2006
--- Genotype of Virus Isolates ---
2000 – 2006 26 2 242000 – 2006 26 2 24
Time Span CNS Outbreaks Wild-Type MutantTime Span CNS Outbreaks Wild-Type MutantNo. of EHV-1No. of EHV-1
Wild-Type OutbreaksWild-Type Outbreaks Mutant OutbreaksMutant Outbreaks
• High neurologic morbidity• High neurologic mortality
• High neurologic morbidity• High neurologic mortality
• Low neurologic morbidity• Low to zero neurologic mortality
• Low neurologic morbidity• Low to zero neurologic mortality
Ack: Dr. G.P. Allen
Clinical Outcome in Relation to Virus Genotype Involved
► In terms of both neurologic-attack and
case-fatality rates, clinical outcome can
vary depending on genotype of EHV-1.
► Outbreaks caused by G2254 tend to be more
extensive and clinically more severe.
► In comparison, A2254 strains associated
with lower neurologic-attack and case-
fatality rates.3/14
Characteristics of Vasculitis
Equine Herpesvirus Myeloencephalopathy
► Perivascular cuffing with mononuclear cells and neutrophils.
► Extension of inflammatory cells from intima into media and adventitia of vessel wall.
► Endothelial proliferation and necrosis.
► Necrosis of media.
► Occasionally, thrombin in vessel lumen.
3/14
EHV-1 Paralysis Results from Endothelial Cell Infection
EHV-1 Paralysis Results from Endothelial Cell Infection
Spinal Cord Blood Vessel of Paralyzed HorseSpinal Cord Blood Vessel of Paralyzed Horse
EHV-1 infected endothelial cellsEHV-1 infected endothelial cells
Fibrin thrombusFibrin thrombus
Inflammatory lymphocytesInflammatory lymphocytes
Ack: Dr. G.P. Allen
Neuropathogenic Strains of EHV-1
► Most frequently but not invariably associated with a single point mutation in the catalytic subunit of the gene (ORF30) encoding the viral DNA polymerase gene.
► "Turbo-charged" versions of wild type virus.
► Total body burden of mutant strains of EHV-1 much greater than wild type virus.
► No evidence of neurotropism.
Summary of properties –
3/14
Viremia in Foals after Inoculation with G2254 Mutant or Wild Type Strains of EHV-1
Viremia in Foals after Inoculation with G2254 Mutant or Wild Type Strains of EHV-1
n = 10 foals/group n = 10 foals/group
Days Post-Inoculation with EHV-1Days Post-Inoculation with EHV-1
Mag
nitu
de
of
Vire
mia
Mag
nitu
de
of
Vire
mia
5 10 15 20 5 10 15 20
00
100100
200200
300300
400400
Mutant EHV-1Mutant EHV-1
Wild Type EHV-1Wild Type EHV-1
Ack: Dr. G.P. Allen
Replicative Capacities of A2254 and G2254 Genotypes of EHV-1
► A2254 and G2254 genotypes differ significantly in
their respective replicative capacities.
► Cell-associated viremia and duration of respiratory shedding greater in cases of G2254
infection.
► Infection with G2254 strains results in vasculitis
in the CNS that is more severe and more
widespread.3/14
Consequences of Mutation on Pathogenicity of Genetic Variants of EHV-1
► Enhanced replicative capacity
► Elevated level of viremia
► More widespread vasculitis
► Greater severity of vasculitis
► Greater mortality from neurologic disease
Ack: Dr. G.P. Allen
Clinical Outcome following Infection with Neuropathogenic Strains of EHV-1
► Infection with G2254 strains may not necessarily
result in development of neurologic disease.
► Individual animal outcomes can be influenced
by age, innate immunity, acquired immunity,
challenge dose, hormonal status and
environmental factors.
3/14
Evidence that A2254 Nucleotide Substitution not the Only Determinant of Neuropathogenicity
Report that 24% of the isolates from horses with neurological disease possessed the A2254 and not the G2254 genotype (Perkins et al., 2009).
Identification of viruses with nonsynonymous nucleotide substitutions in ORF30 besides A2254 to G2254 from horses without signs of neurologic disease (Smith et al., 2010).
Ack: Dr. U. Balasuriya (2011)
(continued)
Sequence analysis of EHV-1 field strains has identified other mutations outside of the small region of ORF30 sequenced by Nugent et al. (2006).
Mutations found in same gene or genes encoding proteins of viral elongation complex or viral envelope proteins.
Ack: Dr. U. Balasuriya (2011)
Evidence that A2254 Nucleotide Substitution not the Only Determinant of Neuropathogenicity
(continued)
Factors Involved in the Epidemiology of Equine Herpesvirus Myeloencephalopathy
► Virus strain.
► Modes of transmission.
► Immune status of individual animals / groups of horses.
► Existence of the carrier state.
► Various management practices.
3/14
Ack: Dr. G.P. Allen
EHV-1 and EHV-4 Infections
► Latency of EHV-1, EHV-4 widespread (40-60%) in adult equids.
► Individual animals may be carriers of one or both viruses.
► Sites of latency of EHV-1 / EHV-4: lymphoreticular tissues associated with the respiratory tract, circulating CD3+ lymphocytes, and the trigeminal ganglia (EHV-1).
Latency –
3/14
(continued)
► Carrier state probably life-long.
► No infectious virus present unless latent virus has been reactivated.
► Latent virus can be reactivated by environmental / pharmacological stimuli.
3/14
EHV-1 and EHV-4 Infections
Latency (cont.) –
Expansion in the Reservoir Size of the Latent G2254 Neuropathogenic EHV-1 Strains in Kentucky TB MaresExpansion in the Reservoir Size of the Latent G2254
Neuropathogenic EHV-1 Strains in Kentucky TB MaresM
uta
nt S
tra
in o
f EH
V-1
(%
of T
ota
l Iso
late
s)M
uta
nt S
tra
in o
f EH
V-1
(%
of T
ota
l Iso
late
s)
DecadeDecade 1960’s 1970’s 1980’s 1990’s 2000’s 1960’s 1970’s 1980’s 1990’s 2000’s
n = 450 abortion isolates of EHV-1n = 450 abortion isolates of EHV-1
5%5%
10% 10%
15% 15%
20% 20%
Smith, K. 2007. Master’s Thesis. University of KentuckySmith, K. 2007. Master’s Thesis. University of Kentucky Ack: Dr. G.P. Allen
Prevalence of Latent, G2254 Neuropathogenic Strains of EHV-1 in TB Mare Population of Kentucky
Prevalence of Latent, G2254 Neuropathogenic Strains of EHV-1 in TB Mare Population of Kentucky
Sub-maxillary lymph nodes collected from 132 necropsied TB mares.Tested for latent EHV-1 DNA by PCR.46% of tested mares harbored latent wild-type EHV-1 DNA.8% of tested mares harbored G2254, neuropathogenic
strains of EHV-1 (=18% of total latent reservoir of EHV-1).
Sub-maxillary lymph nodes collected from 132 necropsied TB mares.Tested for latent EHV-1 DNA by PCR.46% of tested mares harbored latent wild-type EHV-1 DNA.8% of tested mares harbored G2254, neuropathogenic
strains of EHV-1 (=18% of total latent reservoir of EHV-1).
EHV-1 DNA in SMLN tissue of TB mares
EHV-1 DNA in SMLN tissue of TB mares
132 TB broodmares132 TB broodmares
46% WT
8% M8% M
Ack: Dr. G.P. Allen
Development of Equine Herpesvirus Myeloencephalopathy
► Existing levels of cytotoxic T-lymphocyte precursor (CTLP) cells specific for EHV-1 critically important.
► Significantly greater risk in elderly horses (≥ 20 y.o.).
► Significantly greater risk in horses exposed to
ORF30G2,254genotype of EHV-1.
► No significant correlation with pre-exposure levels of serum neutralising antibodies to EHV-1).
Risk factors –
(G.P. Allen, AJVR, 69:1595-1600, 2008) 3/14
Relationship Between EHV-1 Cellular Immunity and Viremic Load
Relationship Between EHV-1 Cellular Immunity and Viremic Load
Cellular Immunity (Pre-Infection CTLp Frequency per million PBMC)
Cellular Immunity (Pre-Infection CTLp Frequency per million PBMC)
Vire
mic
Lo
ad
(L
og 1
0)
Vire
mic
Lo
ad
(L
og 1
0)
Ack: Dr. G.P. Allen
Dr. Roger Doll, 1960’s
Equine Herpesvirus Myeloencephalopathy
► One of 5 clinical syndromes caused by EHV-1 and infrequently, certain strains of EHV-4.
► An emergent disease of increasing veterinary medical and economic significance since 2000.
► Usually a sequel to a primary herpesvirus respiratory infection, febrile illness or abortion.
► Can occur in horses of any age, breed or either gender.
(continued)
Key points –
2/12
► Nature of illness depends on location and severity of lesions in CNS.
► Majority of outbreaks caused by hypervirulent, neuropathogenic (mutant) strains of EHV-1.
► Neuropathogenic EHV-1 strains give rise to much greater body burdens of virus than wild type virus.
► Neuropathogenic EHV-1 strains cause higher morbidity and case-fatality rates.
(continued)
Equine Herpesvirus Myeloencephalopathy Key points (cont.) –
2/12
► Evidence of increasing prevalence of latent infection with neuropathogenic strains of EHV-1.
► Risk factors associated with development of EHM: Age (≥ 20 years old). Infection with neuropathogenic strain of EHV-1. Level of CTLP cells specific for EHV-1.
► Very doubtful current vaccines effective in preventing EHM.
Key points (cont.) –
Equine Herpesvirus Myeloencephalopathy
2/12